Top

News & Events

Archive: 2014

News Archive

2014, A Year of Award Wins for Instinctif Partners’ Life Sciences Clients

London, Manchester, Munich, Boston, Sydney and Melbourne: Instinctif Partners Life Science clients had a successful year as many clients were shortlisted and won prestigious and renowned awards in recognition of their work. 

Read more »

Imperial Innovations: Imperial College London, named as the UK’s top research university

Imperial Innovations (AIM: IVO, "Innovations" or "The Group") is pleased to note the announcement today by Imperial College London that it is the UK’s top research university, according to the results of REF 2014.

Read more »

e-Therapeutics Reports Progress in ETS2101 Phase 1a and Oral Dosing Studies

Oxford and Newcastle, UK – e-Therapeutics plc (AIM: ETX) is pleased to announce that the maximum tolerated dose (“MTD”) has been defined in the current UK trial Phase 1a advanced solid tumour study for ETS2101, the Company’s clinical stage anti-cancer asset.

Read more »

Xellia Pharmaceuticals Focuses on Innovation in Anti-infectives with Formation of Scientific Advisory Board

Copenhagen, Denmark – Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, today announces the formation of a new Scientific Advisory Board (SAB).

Read more »

NetScientific Invests in Next Generation, Immunotherapeutics Company, PDS Biotechnology

London, UK and New York, US - NetScientific (AIM:NSCI), the biomedical and healthcare technology group, today announced it has made an investment in PDS Biotechnology Corporation (‘PDS’).

Read more »

NetScientific Enters Into an Alliance with Healthbox to Invest in New Early-Stage Healthcare Companies

London, UK - NetScientific plc ('NetScientific' or 'the Group', AIM:NSCI), the global biomedical and healthcare technology group, today announced entering into an alliance with Healthbox, a leading healthcare business accelerator, to support the development of early-stage healthcare companies through a program based in Tel Aviv, Israel.

Read more »

Evaluate Ltd - Innovation Driving Positive Outlook for Pharma and Biotech in 2015

LONDON, BOSTON, TOKYO — Innovation will continue to drive the pharma and biotech sectors in 2015 as forecasts point to another prosperous year according to EP Vantage’s latest report, “Pharma & Biotech 2015 Preview.” EP Vantage is the editorial arm of market intelligence firm Evaluate Ltd.

Read more »

Premaitha Health - Results for 7 months to 30 September 2014

Manchester, UK – Premaitha Health plc, a molecular diagnostics company employing next generation DNA analysis technology to develop molecular diagnostic products, announces its maiden results for the seven months ended 30 September 2014.

Read more »

New Addition to NOXXON Supervisory Board Brings Significant US Public Market Expertise

Berlin, Germany and Boston, USA - NOXXON Pharma has appointed Don deBethizy to the Company’s Supervisory Board.

Read more »

Direct biological production of Propylene – Third star on GLOBAL BIOENERGIES’ race to renewable olefins

Evry, France – Global Bioenergies (Alternext Paris: ALGBE) announces having succeeded in the production of bio-sourced propylene by direct fermentation. It is the first time ever an entirely biological production process – i.e. without any chemical step – is reported for propylene, a central building block for the manufacturing of plastics.

Read more »

Prosensa Wins Scrip ‘Biotech Company of the Year’ 2014 Award

Leiden, The Netherlands - Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with a high unmet medical need, is delighted to have won the Scrip ‘Biotech Company of the Year’ Award for 2014, announced last week in London, UK.

Read more »

Orphan Drug Status Granted to Telormedix's lead product Vesimune

Bioggio, Switzerland - Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Vesimune for the treatment of carcinoma in situ (CIS) in the bladder.

Read more »

NetScientific Invests in Breakout Labs’ Portfolio Company EpiBone

London, UK and New York, US - NetScientific (AIM:NSCI), the global biomedical and healthcare technology group, today announced it has made an investment in EpiBone, a revolutionary bone reconstruction company that allows patients to “grow their own bone”. It is the Group’s fourth investment in a Breakout Labs portfolio company since announcing its partnership with Peter Thiel’s revolving philanthropic fund in March 2014.

Read more »

NOXXON Pharma: Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference

Berlin, Germany and Boston, USA, Germany - NOXXON Pharma will disclose promising data from two independent clinical Phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer® olaptesed pegol (NOX-A12) and show preclinical data supporting broad use of olaptesed pegol in combination with anti-cancer therapeutic antibodies at the 56th annual meeting of the American Society of Hematology (ASH) in San Francisco, CA from 06-09 December 2014.

Read more »

GE Healthcare Life Sciences licenses CRISPR gene engineering technology patents from Broad Institute

CHALFONT ST. GILES, UK and NEW YORK, NY, USA – GE Healthcare Life Sciences (NYSE: GE) and the Broad Institute of MIT and Harvard announced today the signing of a non-exclusive license agreement granting GE Healthcare Life Sciences access to intellectual property held by the Broad Institute relating to the CRISPR-Cas9 gene engineering system for research purposes. The CRISPR-Cas9 system allows scientists to modify gene expression in order to gain insights vital to the understanding of disease.

Read more »

Forbion Announces Sale of Portfolio Company PneumRx to BTG for up to EUR 385M (USD 475M)

Naarden, The Netherlands - Forbion Capital Partners (FCP), the leading Dutch VC firm investing in world-class healthcare technologies announces the sale of its portfolio company PneumRx Inc (PneumRx) to BTG plc (LSE: BTG), the UK-based specialist healthcare company for an initial cash consideration of USD 230M (EUR 186M) and up to USD 245M (EUR 199M) in performance-related future milestone payments.

Read more »

Oxford Gene Technology Announces Operational and Financial Highlights for FY 2014

Oxford and Cambridge, UK – Following its successful acquisition and integration of Cytocell Ltd, Oxford Gene Technology (OGT), the molecular genetics company, has provided an operational and financial update for the company’s financial year ended 30 September 2014.

Read more »

Premaitha Health Wins Bionow Investment Deal of the Year Award

Manchester, UK – Premaitha Health (‘Premaitha’) (AIM: NIPT) an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) today announced that Bionow has named the completion of the Company’s reverse listing on the London Stock Exchange’s AIM as its Investment Deal of the Year.

Read more »

e-Therapeutics: Research and Development presentation to Investors and Analysts

Oxford and Newcastle – e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces that it will be holding an investor and analyst presentation and workshop today from 9.30am at its Oxford site.

Read more »

Global Bioenergies Announces Break-through in Direct Biological Production of Butadiene

Evry - November 26, 2014 – Global Bioenergies (Alternext Paris: ALGBE) announces having succeeded in the production of bio-sourced butadiene by direct fermentation. It is the first time ever an entirely biological production process – i.e. without any chemical step- is reported for butadiene, one of the most important petrochemical building blocks.

Read more »

Synthon Initiates Treatment of First Patients in Phase I Trial of anti-HER2 ADC SYD985 based on its Proprietary Linker-Drug Platform

Nijmegen, the Netherlands – Synthon Biopharmaceuticals (‘Synthon’) today announced that the first patients with metastatic solid tumors have commenced treatment with its investigational anti-HER2 antibody-drug conjugate (ADC), SYD985.

Read more »

Nanobiotix secures financing from a major US investor, to address the US market

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today (i) the completion of a private placement with Capital Ventures International (“CVI”) of new shares with warrants attached for a total amount of € 10,393,500, which may be supplemented by an amount of up to € 14,059,500 in case of exercise of all the warrants, (ii) CVI’s commitment to purchase an additional tranche of up to € 10 million that the Company may issue in its discretion (subject to any required corporate authorizations) under the terms and conditions described below, (iii) the Company’s new global development plan and (iv) the registration with the French Autorité des marchés financiers (AMF) of the Company’s reference document, which has been updated with the information relating to the Company’s business to date.

Read more »

Imperial Innovations leads GBP 50 million Series B funding round in Cell Medica

London, UK - Imperial Innovations (AIM: IVO, “Innovations” or “The Group”) has led a £50m series B funding round in Cell Medica (“Cell Medica” or “the Company”) alongside co-investors Invesco Asset Management and Woodford Investment Management. Innovations has committed £15m to the round and following this new investment, will hold a 27.9% stake in the issued share capital of the Company.

Read more »

Cell Medica Announces GBP 50 Million Series B Round

London, UK - Cell Medica, a leading cellular immunotherapy company, today announced the closing of a £50 million Series B investment round with participation from Imperial Innovations, Invesco Perpetual and Woodford Investment Management.

Read more »

BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa’s Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare-Disease Portfolio

San Rafael, California - BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Prosensa Holding N.V. (NASDAQ: RNA) today announced that they have entered into a definitive agreement in which BioMarin will offer to purchase all of the outstanding ordinary shares of Prosensa for $17.75 per share, for a total up front consideration of approximately $680 million. In addition, two approximately $80 million contingent milestones are payable for the approval of drisapersen in the U.S. no later than May 15, 2016 and Europe no later than February 15, 2017, respectively.

Read more »

Autifony Therapeutics announces initiation of Phase IIa study for first-in-class drug to treat tinnitus

London, UK – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has initiated a Phase IIa study in tinnitus subjects with its lead compound AUT00063. This proof of concept study (called the QUIET-1 study, QUest In Eliminating Tinnitus) will explore the potential of AUT00063, Autifony’s first-in-class Kv3 potassium channel modulator, to reduce the symptoms of tinnitus, which is an area of significant unmet medical need.

Read more »

Education and funding are fundamental in fighting the war on antibiotic resistance

Without a change of behavior, antibiotic resistance is an increasingly serious threat to global public health, posing a ‘catastrophic threat’ that could return us  to an era where deaths due to common infections are rife. Be aware, be educated, be responsible and support actions to ensure that future generations can enjoy modern medical advances made possible through keeping bacterial infections at bay through the effective use of antibiotics says Instinctif Partners.

Read more

Read more »

DNAe Highlights the Urgent Need for Fast Diagnostics to Help Tackle the Growing Threat of Antibiotic Resistance

London, UK – DNA Electronics (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary point-of-need test for blood infections, highlights the urgent need for fast diagnostics to help tackle the growing threat of antibiotic resistance.

 

Read more »

On European Antibiotic Awareness Day Xellia Pharmaceuticals Strengthens Commitment to Innovation in Anti-Infectives with New API R&D Center of Excellence in Oslo

Copenhagen, Denmark - Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, today announced the opening of a new active pharmaceutical ingredients (API) R&D Center of Excellence in Oslo, Norway.

Read more »

Global Bioenergies: Successful First Trial in its Industrial Pilot

Evry (France) –  Global Bioenergies (Alternext Paris: ALGBE) announces having successfully carried out the first isobutene production trial in its industrial pilot of Pomacle-Bazancourt. Delivered on the Pomacle-Bazancourt site in July, the industrial pilot installation has since been taken through a series of mechanical and functional validations. A production run was initiated on November 3rd, 2014, and resulted in the very first production of fermentative isobutene in an industrial environment. This achievement is documented in a short movie available on Global Bioenergies’ website.

Read more »

Prosensa Announces 3rd Quarter 2014 Financial Results and Recent Corporate Developments

Leiden, The Netherlands — Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported financial results for the third quarter ending September 30, 2014 and provided an update on the regulatory plans and re-dosing for drisapersen, our lead exon-skipping drug candidate, and next steps for our follow-on exon skipping compounds for the treatment of Duchenne muscular dystrophy (DMD).

Read more »

Nanobiotix revenue for the 3rd quarter of 2014

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the third quarter of 2014.

Read more »

Instinctif Partners Life Sciences’ Clients Shortlisted for the BioNewsRound Award 2014

London, Manchester: Instinctif Partners Life Sciences supports its clients with entries to awards and is delighted that four of its clients have been shortlisted for the BioNewsRound Award 2014. Clients Autifony, Clinigen, Novabiotics and Premaitha Health are up against F-Star and the Centre for Therapeutic Target Validation.

Read more »

GE Healthcare Life Sciences to Open Biopharmaceutical Technology and Training Laboratory in Turkey

Chalfont St Giles, UK and Istanbul, Turkey – GE Healthcare Life Sciences (GE:NYSE), a global tools, technologies and services provider in life science research and biopharmaceutical manufacturing, will open a Technology and Training Laboratory to support Turkey’s expanding biopharmaceutical and biotechnology industry. A key component of GE’s Turkey Innovation Center in Istanbul, the laboratory will open to customers, industry and academic partners from mid-2015. This adds to GE’s global network of biopharmaceutical customer training and technology facilities in the US, UK, China, India and Sweden.

Read more »

Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects With Isolated, Elevated Lipoprotein(a) Levels

Naarden, The Netherlands – Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, today announced the complete enrolment of a study with TA-8995 in asymptomatic subjects with isolated, severely elevated Lipoprotein(a) (Lp(a)), which was initiated in September of this year.

Read more »

Instinctif Partners Welcomes New Members to its London and Munich Life Sciences Teams

London, UK and Munich, Germany: The Life Science team of Instinctif Partners, the international business communications consultancy, announces the appointment of six new team members who have recently joined its offices in London and Munich. Working as an integral part of the global Instinctif Partners Life Sciences team, the new members will support clients across a wide spectrum of retainer and project PR accounts.

Read more »

Oncoethix starts Phase 1b Trials of OTX015 in the Treatment of Advanced Solid Tumors (OTX015_107) and Glioma (OTX015_108)

Lausanne, Switzerland – Oncoethix, the Swiss-based specialist in oncology drug development, today announced that the first patient has been enrolled in an international, open-label, non-randomized, multicenter Phase 1b trial of OTX015 in advanced solid tumors.  The trial will be coordinated by Dr Lillian Siu, MD, of the Princess Margaret Hospital, Toronto, Canada, who is Professor of Medicine at the University of Toronto, and Director of the Phase 1 program.

Read more »

Polyphor’s lead antibiotic POL7080 receives Qualified Infectious Disease Product (QIDP) designation from the FDA

Allschwil, Switzerland - Polyphor Ltd, a privately held pharmaceutical company specialized in the discovery and development of macrocycle drugs, announced today that the U.S. FDA designated POL7080 as a Qualified Infectious Disease Product (QIDP) for the treatment of Ventilator-Associated Bacterial Pneumonia (VABP) caused by Pseudomonas aeruginosa.

Read more »

Prosensa Holding N.V. to Webcast Conference Call Discussing 3rd Quarter 2014 Financial Results and Corporate Update on November 17, 2014

Leiden, The Netherlands - Prosensa Holding N.V. (NASDAQ: RNA) today announced that the Company will host a conference call and live audio webcast on Monday, November 17, 2014 at 8:00 a.m. US Eastern Time (2:00 p.m. Central European Time) to report its third quarter financial results and provide a corporate update.

Read more »

Histide Raises CHF 4.5 M (USD 4.6 M) Series A Investment Round to Advance Its Pioneering Recoding Therapeutics™ Technology

Schindellegi, Switzerland  – Histide AG, a privately held Swiss biotech company pioneering a new class of non-mutagenic extracellular technology, Recoding Therapeutics™, has announced today the closure of a series A financing round of CHF 4.5 Million to expand further its IP licensing pipeline and clinical development of its innovative Recoding Molecules™. The round was led by PARTER Capital Group AG, Switzerland, and a group of private investors.

Read more »

Mucosis Presents Data on Intranasal Respiratory Syncytial Virus Vaccine SynGEM® at RSV2014 Symposium

Groningen, the Netherlands – Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases, will present research on its lead intranasal vaccine candidate SynGEM®, a vaccine candidate being researched to prevent infection with respiratory syncytial virus (RSV), at the 9th International Respiratory Syncytial Virus Symposium (RSV2014), taking place in Stellenbosch, South Africa from 9-13 November.

Read more »

Premaitha Health Prepares for Launch of the IONA® test with Key Commercial Appointment

Manchester, UK – Premaitha Health (‘Premaitha’) (AIM: NIPT), an innovative molecular diagnostics company bringing advantages in Next Generation DNA sequencing to non-invasive prenatal testing (NIPT), today announces the appointment of Yves Derveaux as Regional European Sales Consultant for Southern Europe as it prepares for the launch of the IONA® test.

Read more »

New Sheriffs in Town: GE’s Crotonville Training Center welcomes Five Law Enforcement Leaders for Executive Education

Chalfont St. Giles, UK – GE Healthcare Life Sciences (NYSE:GE) announced today that five US law enforcement leaders have been selected to attend a world-class GE executive leadership development program in New York. Developed in close collaboration with the Major County Sheriffs’ Association (MCSA), the course will take place at GE’s Crotonville Management Development Institute, which was founded in 1956 and was the world’s first major corporate university.

Read more »

Professor Richard F. Neville and Mr Eric Chemla Join the Independent Vascular Flow Technologies’ Scientific Advisory Board

Dundee, UK, – Vascular Flow Technologies, the medical device company using proprietary Spiral Laminar Flow (SLF) technology to replicate natural blood flow for enhanced patient outcomes, today announces the appointment of Richard F. Neville, MD, FACS and Mr Eric Chemla, FRCS to their Scientific Advisory Board.

Read more »

Clinical Network Services (CNS) signs cooperative agreement with BD Consultancy

Brisbane, Australia - Clinical Network Services (CNS) an integrated product development company based in Australia and New Zealand providing broad services in the planning, implementation and delivery of preclinical, Phase 1 and 2 trials, and Biologics Development Consultancy B.V. (BDC), a team of consultants providing regulatory and product development advice on the development and commercial production of biotechnological, biological and drug products, today announced that they have signed a cooperative partnership agreement where CNS, and in particular the BioDesk consultancy, and BDC will mutually expand the expertise they can together offer their clients.

Read more »

Gallus BioPharmaceuticals and GE Healthcare Life Sciences win global bioprocessing industry award

St. Louis, Missouri, USA and Chalfont St Giles, UK – Gallus BioPharmaceuticals, LLC, (Gallus), a premier, full service biopharmaceutical contract development and manufacturing organization (CDMO), and GE Healthcare Life Sciences (NYSE: GE) have been jointly recognised for the successful design and construction of an advanced single-use biomanufacturing facility as winners of the BioProcess International (BPI) Award for Excellence in Facility Design and/or Retrofit. Gallus BioPharmaceuticals was recently acquired by DPx Holdings B.V. and now operates under the Patheon business unit.

Read more »

OGT Initiates Clinical Trial of New Array-Based Non-Invasive Prenatal Test (NIPT)

Oxford and Cambridge, UK – Oxford Gene Technology (OGT), the molecular genetics company, today announced it is initiating a clinical trial of a new microarray-based non-invasive prenatal test (NIPT) for Down’s syndrome.

Read more »

GE Healthcare Life Sciences wins prestigious bioprocessing industry award

CHALFONT ST. GILES, UK – GE Healthcare Life Sciences (NYSE:GE) has won a BioProcess International (BPI) industry award for excellence in bioprocessing facility design.  The BPI awards, voted for by bioprocess experts and hosted by industry publication BioProcess International, recognize outstanding products, services, partnerships and people that have had the greatest positive impact across the biopharmaceutical manufacturing industry. The winners were announced at a special ceremony during the 2014 BPI International Conference and Exhibition in Boston, Massachusetts, USA.

Read more »

Auspherix Secures Additional AU$1Million From MRCF to Advance its Antibiotic Pipeline

Sydney - Australia - Auspherix Pty Ltd, an early stage anti-infectives company developing novel antibiotics to treat resistant bacterial disease has secured a further AU$1 million in a series A financing from Australia’s Medical Research Commercialisation Fund (MRCF), to progress its antibacterial compounds through development studies.

Read more »

Xellia Pharmaceuticals Welcomes HM the Queen of Denmark to Zagreb R&D Center of Excellence During State Visit to Croatia

Copenhagen, Denmark and Zagreb, Croatia – Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, today announced that HM the Queen Margrethe II of Denmark visited the Company’s Product and Innovation R&D Center of Excellence in Zagreb on Wednesday 22 October during her State visit to Croatia.

Read more »

Karus Therapeutics Appoints New Head of Clinical Development and Head of Biology

Oxford, UK – Karus Therapeutics (‘Karus’), a leader in the development of innovative medicines for the treatment of inflammatory diseases and cancer, today announced that it has further strengthened its R&D team with two new appointments; Dr Simon Roitt, who joins as Head of Clinical Development and Dr Peter Finan, who has been appointed as Karus’s Head of Biology.

Read more »

Liftstream Report Finds Ten Men for Every Woman Present in Biotech Boardrooms

London – Liftstream Ltd, a company providing executive recruitment services to the biotechnology sector, announces the publication of its new gender diversity report, “Diversifying the Outlook – The X&Y of Biotechnology Leadership”, a detailed analysis of women leaders in European and US life biotech companies. The research covers 700 companies, 60 C-level interviews and 530 survey respondents.

Read more »

Mucosis Presents Data on Intranasal RSV Vaccine SynGEM® at Vaccines 2014 Conference

London, UK – Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases, will present research on its lead intranasal vaccine candidate SynGEM®, a vaccine candidate being researched to prevent infection with respiratory syncytial virus (RSV), at Vaccines 2014, taking place in London from 20-22 October.

Read more »

Appointment of Executive Director

Oxford, UK – e-Therapeutics plc (AIM: ETX), the drug discovery and development company, is pleased to announce it is appointing Sean Nicolson, aged 48, to the Board of Directors as an Executive Director.  The appointment is expected to become effective in 2015 following Mr. Nicolson’s resignation from Bond Dickinson LLP and the fulfilment of his existing contractual obligations.

Read more »

Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that it has received approval from the French National Security Agency for Medicines and Health Products (ANSM) to start its Phase II/III registration trial of its lead product, NBTXR3, in patients with locally advanced Soft Tissue Sarcoma (STS).

Read more »

Imperial Innovations Group plc - Four IPOs, £150m raised and portfolio value up 38% to £252m

Imperial Innovations Group plc (AIM: IVO, “Innovations” or “the Group”), a leading technology commercialisation and investment group, has published its results for the year ended 31 July 2014.

Read more »

Auspherix and Domainex Announce Collaboration to Develop New Drugs to Treat Antibiotic-resistant Bacterial Infections

Cambridge, UK and Sydney, Australia - Domainex Ltd. and Auspherix Pty Ltd today announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate.

Read more »

Nanobiotix reaches the second milestone payment of Bpifrance dedicated to NBTXR3 development in liver cancers

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the second payment of €1.144 k from Bpifrance as part as the funding granted to support the NICE consortium.

Read more »

Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophy

LEIDEN, The Netherlands – Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that it has commenced the submission process for a New Drug Application (NDA) regulatory filing to the United States Food and Drug Administration (FDA) for its lead exon-skipping drug candidate, drisapersen, for treating Duchenne muscular dystrophy (DMD). The drug received “Fast Track status” from the FDA, making it eligible for a rolling review of an NDA and was also granted “Breakthrough Therapy Designation” in June 2013.

Read more »

OGT Named OBN’s Best Medtech Dealmaker

Oxford and Cambridge, UK – Oxford Gene Technology (OGT), the molecular genetics company, has won the Best Medtech Dealmaker award for the second year in a row at the OBN awards held on Thursday 2 October. The award recognises OGT’s acquisition of Cambridge-based Cytocell Limited (Cytocell), a leading provider of DNA technology for the detection of gene rearrangements related to inherited genetic disease and cancer.

Read more »

PharmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer today announces the update of the development plan for NBTXR3. Nanobiotix and its partner PharmaEngine Inc., a biopharmaceutical company focusing on the development of in-licensed oncology drugs, reinforce their collaboration to obtain faster market authorization for NBTXR3 in the Asia-Pacific region.

Read more »

NovaBiotics’ Dr Deborah O’Neil Named EY UK Health Products & Services Entrepreneur of 2014

Aberdeen, UK – NovaBiotics Ltd, the Aberdeen-based, clinical-stage biotechnology company (“NovaBiotics” or the “Company”), today announced that Dr. Deborah O’Neil, the Company’s Chief Executive Officer, was named  EY UK Health Products & Services Entrepreneur of the Year 2014 at the awards dinner held at The Brewery, London last night, attended by over 600 of the country’s top business leaders.

Read more »

Atopix Therapeutics Secures Funding from SR One to Advance Development of CRTH2 Antagonists in Eosinophilic Disease

Abingdon, UK — Atopix Therapeutics Ltd (“Atopix”), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, today announced the addition of SR One to its investor syndicate and the appointment of Dr Deborah Harland, Partner, SR One to the Board of Directors, following an extension to its Series A financing. The additional funds provided by SR One will be used to complete the evaluation of Atopix’s lead CRTH2 antagonist OC459 in atopic dermatitis and to assess the safety and pharmacokinetic profile of its highly potent back-up molecule ATX2417 in Phase I studies.

Read more »

Medtech Market to Achieve Global Sales of $514 Billion by 2020; Megamergers Set to Reshuffle Top Players

LONDON, BOSTON, TOKYO – The medical technology sector is expected to grow at a compound annual growth rate of 5 percent per year between 2013 and 2020, according to the latest forecasts from market intelligence firm Evaluate Ltd. Its new report, “EvaluateMedTech World Preview 2014, Outlook to 2020,” released today at the AdvaMed 2014 conference in Chicago, reveals that global medtech sales are expected to reach $514 billion by 2020, with megamergers reshaping the lineup of industry leaders.

Read more »

Innovative Health Technology Clients Appoint Instinctif Partners to Provide Communications Counsel

London, Manchester, Munich, Boston, Sydney, Melbourne: In the third quarter of 2014, the Life Sciences team of international business communications consultancy, Instinctif Partners, won five new retainer mandates, as well as securing three new project clients.

Read more »

Gallus BioPharmaceuticals and GE Healthcare Life Sciences named as finalists for global bioprocessing industry award

St. Louis, Missouri, USA and Chalfont St Giles, UK – Gallus BioPharmaceuticals, LLC, (Gallus), a premier, full service biopharmaceutical contract development and manufacturing organization (CDMO), and GE Healthcare Life Sciences (NYSE: GE) have been jointly recognised for the successful design and construction of an advanced single-use biomanufacturing facility by being shortlisted for the BioProcess International (BPI) Award for Excellence in Facility Design and/or Retrofit. Gallus BioPharmaceuticals was recently acquired by DPx Holdings B.V. and now operates under the Patheon business unit.

Read more »

Promosome and GE Healthcare Life Sciences nominated for global bioprocessing industry award

New York, NY, USA and Chalfont St Giles, UK – Promosome LLC and GE Healthcare Life Sciences, (NYSE: GE), announced today that the companies’ collaboration to develop and bring to market Promosome’s innovative cell line development technologies for increasing expression levels for hard-to-manufacture proteins has been shortlisted for a leading industry award.

Read more »

GE Healthcare Life Sciences named as finalist for four bioprocess industry awards

CHALFONT ST GILES – GE Healthcare Life Sciences (NYSE:GE) announced today that the company has been shortlisted as a finalist for four BioProcess International (BPI) Awards. These prestigious awards, which are voted for by experts in the field and supported by bioprocess specialist publication BioProcess International – celebrate and recognize the outstanding people, organizations and technologies that have significantly changed, impacted, and advanced the efficiency of biotherapeutic development and manufacturing. Two of the nominations received are for GE Healthcare’s people and technologies directly, whilst a further two are the result of collaborations with Promosome LLC and Gallus BioPharmaceuticals LLC.

Read more »

Forbion Capital Partners Announces First Close of FCF III

Naarden, The Netherlands – Forbion Capital Partners (Forbion) today announced that it has raised EUR 92m (USD 120m) in a first close of its new fund FCF III.

Read more »

NetScientific’s subsidiary, Glycotest Begins a New Research Collaboration with Oncimmune

Cambridge, UK – NetScientific (AIM: NSCI), the global biomedical and healthcare technology group today announces its portfolio company Glycotest, Inc. has entered into a research collaboration with Oncimmune Ltd to explore the combined application of their proprietary tests in the early detection of liver cancer.

Read more »

Ability of Semiconductor DNA Sequencing to Transform Healthcare and Save Lives Recognised by the 2014 Faraday Medal to Professor Chris Toumazou

London, UK – DNA Electronics (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary point-of-need test for sepsis, announces today that its founder, Chairman and CEO Professor Chris Toumazou FRS, FREng, FMEDSci, FIET, FIEEE, FCGI, FRSM has been awarded the UK Institution of Engineering and Technology (IET)’s highest honour, the 2014 Faraday Medal. Named after Michael Faraday, the medal which dates back to 1922 recognises Professor Toumazou’s pioneering work in the invention of semiconductor DNA sequencing and its ability to revolutionise healthcare and save lives.

Read more »

Mucosis Presents Infectious Diseases Vaccines Pipeline Update at SACHs Associates 14th Annual Biotech in Europe Forum

Groningen, The Netherlands – Mucosis B.V., a clinical stage biotechnology company developing novel vaccines for infectious diseases, will present updates on its research and development program at the Biotech in Europe Forum taking place in Basel, Switzerland 30 September through 01 October 2014.

Read more »

ADC Therapeutics Expands Team

Lausanne, Switzerland and London, UK – 30 September 2014 – ADC Therapeutics (ADCT, a portfolio company of Auven Therapeutics) the oncology drug development company focused on Antibody Drug Conjugates (ADCs) targeting major cancers, today announced a significant expansion of its team as the Company’s first ADCs enter clinical development.

Read more »

Clinigen Group plc Receives FDA’s First Ever Drug Shortage Assistance Award

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM:CLIN) the global specialty pharmaceutical company, today announces that it has received the first Drug Shortage Assistance Award from the US Food and Drug Administration (FDA) in recognition of its contribution in addressing a US shortage of Foscavir® (foscarnet sodium) injection.

Read more »

Prosensa extends the re-dosing of drisapersen in Europe in patients with Duchenne muscular dystrophy

Leiden, The Netherlands – Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that it has extended its comprehensive program of re-dosing of drisapersen in patients with Duchenne muscular dystrophy (DMD) into Europe, with the PRO051-02/DMD114673 sites re-opening, beginning with Belgium. This follows quickly on the re-dosing program that began in the United States (US) last week.

Read more »

Cell Reports Publication on the Mechanism of Action of NOXXON’s Anti-SDF-1 Spiegelmer® Olaptesed Pegol (NOX-A12) in Preclinical Multiple Myeloma Models

Berlin, Germany and Boston, USA – NOXXON Pharma announced today the publication of a new study in Cell Reports, entitled “SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy”. The study of the hematological malignancy multiple myeloma in a mouse model was conducted by scientists from Dana-Farber Cancer Institute at Harvard Medical School, Boston, USA and NOXXON Pharma.

Read more »

Prosensa publishes a sensitive, reproducible and objective methodology for dystrophin analysis in patients with Duchenne muscular dystrophy

LEIDEN, The Netherlands– Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that the results of its research into developing an accurate and reproducible method for the measurement of dystrophin in patients with Duchenne muscular dystrophy (DMD) and Becker’s muscular dystrophy (BMD) have been published in the online peer reviewed journal PLOS ONE (http://bit.ly/ZJ8ShM).

Read more »

Instinctif Partners Hosts Cancer Research Technology Event on Innovative Cancer Diagnostics and Treatments

London: Instinctif Partners (formerly College Hill) sponsored & hosted a breakfast briefing with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK, entitled “Innovative approaches to better diagnose and treat cancer patients: analysis of blood borne tumour cells and DNA” on 23 September 2014.

Read more »

Cell Medica announces the appointment of Andrea Ponti as Non-Executive Director

London, UK – The Board of Cell Medica is pleased to announce the appointment of Andrea Ponti as a non-executive director.

Read more »

DNAe Completes its Leadership Team with Key Operational and R&D Appointments as it Takes Forward its DNA Diagnostic Test for Sepsis

London, UK  – DNA Electronics (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary point-of-need test for sepsis, today announced the completion of its leadership team with the appointment of Kevin Stearn as Operational Director, and Dr David Edington as Vice President, R&D.

Read more »

Clinigen Full Year Results - Underlying EBITDA up 19.8% and EPS up 22%

Burton-on-Trent, UK  – Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN), the global specialty pharmaceuticals business, has today published its preliminary results for the 12 months ended 30 June 2014.

Read more »

Telormedix granted European Patent for Vesimune

Bioggio, Switzerland - Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and infectious diseases, announced today that it has been granted the European Patent No. 2393474 entitled "Pharmaceutical compositions comprising imidazoquinolin (amines) and derivatives thereof suitable for local administration" by the European Patent Office.

Read more »

Clinical Network Services (CNS) and Ventac Partners sign cooperative partnership

Brisbane, Australia & Copenhagen, Denmark - Clinical Network Services (CNS) Pty Ltd, an integrated service consultancy focused on product development, headquartered in Australia with offices in New Zealand, the UK and the USA and Ventac Partners, a dedicated life science consulting firm with offices in Europe, USA and Asia, today announced that they have signed a cooperative partnership agreement where CNS, and in particular the BioDesk consultancy, will become the preclinical, clinical and regulatory experts that Ventac can draw upon in support of portfolio companies and clients. 

Read more »

Nanobiotix expands operations into the USA as part of its international development strategy

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the opening of its first US office in Boston, Massachusetts, the global center for life sciences.

Read more »

AmpliPhi Announces Departure of CEO

Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia – AmpliPhi BioSciences Corporation (OTC:APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage based therapies to treat drug resistant bacterial infections, today announced that Philip J. Young has stepped down from his role as President and CEO. Mr Young’s resignation was by mutual agreement with AmpliPhi’s Board of Directors with his departure from the Company being effective Monday, September 15.

Read more »

Clinigen Group launches New First-in-Class Antibiotic VIBATIV® (telavancin) for MRSA related Hospital-Acquired Pneumonia across Europe

Burton-on-Trent, UK Clinigen Group plc (‘Clinigen’ or the ‘Group’) (AIM: CLIN), the specialty global pharmaceutical company, today announced that the new first-in-class bactericidal, once-daily, injectable antibiotic VIBATIV® (telavancin), is now available to prescribe in Europe for the treatment of adults with nosocomial pneumonia (also known as hospital acquired pneumonia – HAP), including ventilator associated pneumonia (VAP), known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA) when other alternatives are not suitable.

Read more »

Biotech Venture Capital Firm Aglaia Launches New $65 Million

Bilthoven, the Netherlands – Dutch venture capitalist Aglaia has announced the launch of Aglaia Oncology Fund II. 

Read more »

NOXXON Pharma Expands Management Team by Appointing

Berlin, Germany and Boston, Massachusetts – NOXXON Pharma has appointed Don Munoz to the newly created position of Chief Financial Officer. Mr. Munoz will strengthen the executive management board and will be based in NOXXON’s new subsidiary office in Boston, MA.

Read more »

Prosensa announces commencement of re-dosing of drisapersen in North America in patients with Duchenne muscular dystrophy

LEIDEN, The Netherlands – Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that a comprehensive program of re-dosing has commenced, with the first patients now re-dosed in the United States.

Read more »

Instinctif Partners Life Sciences’ Clients Shortlisted for EuropaBIO and Scrip Awards

London, Manchester, Munich, Boston, Sydney, Melbourne: Instinctif Partners Life Science supports its clients with entries to awards and is delighted that this month its clients have been shortlisted for an number of Awards  including the EuropaBio Most Innovative Biotech 2014 Award and the 2014 Scrip Awards.

Read more »

NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex® for the Treatment of Cystic Fibrosis

Aberdeen, UK – NovaBiotics Ltd, the Aberdeen-based clinical-stage biotechnology company (“NovaBiotics” or the “Company”), today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for Lynovex® (NM001), the Company’s first-in-class  therapeutic candidate for the treatment of Cystic Fibrosis (CF).

Read more »

e- Therapeutics Half Yearly Results

Oxford, UK - e-Therapeutics plc (AIM: ETX), the drug discovery and development company, today announces its half year results for the six months ended 31 July 2014.

Read more »

Vaxxas Initiates Research Project on Advancing Next Generation Technology for Polio Vaccine Delivery

Brisbane, Queensland, Australia and Cambridge, MA, USA – Vaxxas, a biotechnology company commercializing a novel vaccine delivery platform, today announced the initiation of a research project to evaluate Vaxxas' proprietary Nanopatch™ platform for delivery of polio vaccine.  

Read more »

Xellia Pharmaceuticals Seeks New Talent as it Expands

Copenhagen, Denmark and Raleigh, North Carolina –  Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, announces a range of new employment opportunities at its dedicated lyophilized (freeze-dried) vial manufacturing facility in Raleigh, North Carolina recently acquired from Fresenius Kabi.

Read more »

Prosensa announces 12 presentations at the 19th International Congress of the World Muscle Society in Berlin

LEIDEN, The Netherlands - Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that it will be presenting 12 abstracts at the 19th International Congress of the World Muscle Society (WMS), to be held in Berlin, Germany from October 7-11, 2014.

Read more »

Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy

Leiden, The Netherlands – Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that the full data from its exploratory, double-blind, placebo-controlled Phase II study (DEMAND II/ DMD114117/ NCT01153932) of drisapersen in patients with Duchenne muscular dystrophy (DMD) have been published in Lancet Neurology http://bit.ly/1rSMpeJ.

Read more »

Two Presentations at International Conferences of Preclinical Data on NOXXON’s anti-C5a Spiegelmer®, a Potential Drug in Pneumococcal Pneumonia-Induced Sepsis

Berlin, Germany - Scientists of Charité - Universitätsmedizin Berlin and NOXXON Pharma are invited to present new preclinical data about effects of NOX-D19, a Spiegelmer® neutralizing the complement component C5a, in pneumococcal pneumonia-induced sepsis.

Read more »

Source BioScience: Appointment to the Board

Nottingham, UK – Source BioScience plc (LSE: SBS) the international laboratory services and products business, announces that Tim Metcalfe will join the Board as Group Finance Director with immediate effect.  Tim succeeds Rob Bakewell who has left the Group to pursue other opportunities.

Read more »

Clinigen Group: Notification of Full Year Results Date

Burton-on-Trent, UK –  Clinigen Group plc (AIM: CLIN), the global specialty pharmaceuticals and services company, will announce its full year results for the year ended 30 June 2014 on Wednesday, 24 September 2014.

Read more »

Cerenis receives EMA Orphan Drug Designations for CER-001 for the treatment of ApoA-I and ABCA-1 deficiencies

Toulouse, France and Ann Arbor, Michigan, USA - Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic, for the treatment of cardiovascular disease, announced today that it has received two separate Orphan Drug Designations from the European Medicines Agency (EMA) for the use of CER-001 in the treatment of patients with rare genetic defects in HDL synthesis/maturation pathways, specifically apoA-I deficiency and ABCA1 deficiency.

Read more »

Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia

Naarden, The Netherlands – Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today that it has received very positive results in its Phase 2b TULIP clinical trial, a double blind, placebo controlled, Phase 2b dose ranging study of TA-8995 (DEZ-001), as monotherapy and in combination with statins for treating dyslipidemia.

Read more »

Nanobiotix Half Year Results for the six months ended 30 June 2014

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has published today its half year results for the six months ended 30 June 2014.

Read more »

Vaxxas Selected as World Economic Forum Technology Pioneer 2015

Brisbane, Queensland, Australia, and Cambridge, Mass., USA – Vaxxas, a biotechnology company commercializing a novel vaccine delivery platform, has been named a 2015 Technology Pioneer by the World Economic Forum. Vaxxas is one of 24 emerging technology companies from around the world and across all industries recognized for their potential to transform the future of business and society.

Read more »

Mood Lifts for Medtech in First Half of 2014 While Pharma Sector Faces New Struggles

London, Boston, Tokyo - An M&A frenzy that accounted for nearly $90 billion of equity set the pace for the first half of 2014 in the pharma and biotech sectors, but a slowdown in IPOs and six months of volatile market activity could tarnish the year’s shimmering start. Meanwhile, skies appear to have brightened for the medtech sector as improvements, largely fueled by multibillion-dollar deals, occurred across the board.

Read more »

Clinigen Group Further Strengthens Oncology Support Portfolio with Acquisition of Ethyol® (amifostine), from AstraZeneca

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’) (LSE: CLIN) (AIM: CLIN) the specialty global pharmaceutical company today announces the acquisition of the global rights to the oncology support therapy, Ethyol® (amifostine) from AstraZeneca.

Read more »

Source BioScience Half Year Report for the Six Months Ended 30 June 2014

Nottingham, UK - Source BioScience plc (LSE: SBS) the international laboratory services and products business publishes its Half Year Report for the six months ended 30 June 2014.

Read more »

Novogen Announces Results of General Meeting of Shareholders

Sydney, Australia - 13 August 2014 - Australia-US biotechnology company, Novogen Ltd. (ASX: NRT, NASDAQ: NVGN), an oncology and degenerative diseases drug development company, today announced the results of its General Meeting of Shareholders, which was held on August 13 in Sydney, Australia.

Read more »

Novogen Receives Funding Support to Commence Studies in Muscular Dystrophy

Sydney, Australia – The Australian biotechnology company, Novogen Limited (ASX: ‘NRT’; NASDAQ: ‘NVGN’), today announced receipt of funding from the FSHD Global Research Foundation as part of the Company’s efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD).

Read more »

Prosensa and CureDuchenne Strengthen Long-term Collaboration with an Additional €5M to Advance DMD Pipeline

Leiden, The Netherlands –  Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that an affiliate of CureDuchenne, a US national nonprofit organization dedicated to finding a cure for Duchenne Muscular Dystrophy (DMD), will provide Prosensa with up to €5 million by means of convertible promissory notes to support the company and accelerate the development and patient access of much needed DMD therapies. The closing of €4.5 million of the notes is contingent upon specified milestones in the advancement of drisapersen and the Company’s other exon skipping candidates in Prosensa’s DMD portfolio.

Read more »

New ISPE White Paper Provides Guidance on Development and Implementation of Regulatory-Compliant Patient Access Programs

Burton-on-Trent, UK –  Clinigen Group (‘Clinigen’) (AIM: CLIN), the specialty global pharmaceutical company, announces the publication of a new International Society for Pharmaceutical Engineering (ISPE) white paper developed in collaboration with an interdisciplinary team of industry experts chaired by Mark Corbett, SVP Clinigen Global Access Programs (Clinigen GAP). The white paper describes regulatory-compliant mechanisms that enable access to medicines for patients who have exhausted all other treatment options.

Read more »

Instinctif Partners and SwedenBIO Partner to Promote Nordic Life Science Days for Second Year

London: Instinctif Partners, the international business communications consultancy, announces it will be working in partnership with SwedenBIO for the second year running, to promote Nordic Life Science Days, the largest Nordic life sciences event.

Read more »

Forbion Announces Sale of Portfolio Company, Santaris Pharma, to Roche for up to $450m

Naarden, The Netherlands - Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies announces the sale of its portfolio company, Santaris Pharma A/S for a total consideration of up to $ 450 million, of which an upfront cash payment of $250 million and additional contingent payments of up to $200 million based on the achievement of certain predetermined milestones.

Read more »

Seventure’s Portfolio Company Santaris Pharma Sold for Up To US $450m to Roche

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation, today announces the successful trade sale of Santaris Pharma A/S to Roche for up to $450 million.

Read more »

Prosensa Holding N.V. to Webcast Conference Call Discussing 2nd Quarter 2014 Financial Results and Corporate Update on August 12, 2014

Leiden, The Netherlands - Prosensa Holding N.V. (NASDAQ: RNA) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 12, 2014 at 8:00 a.m. US Eastern Time (2:00 p.m. Central European Time) to report its second quarter financial results and provide a corporate update.

Read more »

BioGasol Establishes Licensed Carbofrac® Reactor Manufacture by Sweetwater Energy

Copenhagen, Denmark - BioGasol ApS (“BioGasol”), the market leader in advanced pretreatment reactors for the thermochemical extraction of sugar from biomass, announces that it has non-exclusively licensed Sweetwater Energy Inc. (“Sweetwater”), the Rochester, NY-based cellulosic sugar producer, to manufacture, for its own use, BioGasol’s proprietary Carbofrac® reactors.

Read more »

NOXXON Initiates Phase IIa Study of Anti-Hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) in Dialysis Patients with EPO-hyporesponsive Anemia

Berlin, Germany - NOXXON Pharma today announced the treatment of a first patient with its anti-hepcidin Spiegelmer® lexaptepid pegol (NOX-H94) in a phase IIa proof-of-concept clinical trial to treat erythropoietin (EPO)-hyporesponsive anemia in dialysis patients. This is the fourth clinical trial with lexaptepid pegol. The multi-center, placebo-controlled study will examine the pharmacokinetics, pharmacodynamics, efficacy and safety of single and multiple doses of lexaptepid pegol in EPO-hyporesponsive dialysis patients with anemia.

Read more »

Novogen and CanTx Appoint Contract Manufacturers to Produce Clinical Batches of Cantrixil™

Sydney, Australia – Oncology drug developer, CanTx Inc, and its parent company, Novogen Ltd. (ASX; NRT: NASDAQ; NVGN), today announced that they have named two key contract manufacturing organizations (CMOs) to produce clinical batches of the experimental anti-cancer drug, Cantrixil™. CanTx and Novogen expect to file an Investigational New Drug (IND) application for Cantrixil early next year and to advance this compound into the clinic by mid- 2015.

Read more »

Year End Trading Update

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN), the specialty global pharmaceutical company, today provides the following trading update for the year ended 30 June 2014.

Read more »

HealthUnlocked, Europe’s Largest Social Network for Health, Expands to the US

London, UK – HealthUnlocked, the leading social network for health related information, today announces its official U.S. launch. The digital health company, founded in 2010 by CEO Jorge Armanet and Chief Medical Officer Dr Matt Jameson Evans, is one of the fastest growing startups in the UK health tech sector, growing exponentially since 2011 and last month received three million site visits. HealthUnlocked already provides NHS Choices’ user-generated, interactive content via the communities section.

Read more »

OGT Awarded £200K Contract by SBRI to Develop Innovative Whole Genome NGS Analysis Software

Oxford and Cambridge, UK –  Oxford Gene Technology (OGT), the molecular genetics company, today announced it has been awarded a £200K phase one development contract by the Small Business Research Initiative (SBRI) healthcare competition.

Read more »

Instinctif Partners Selected as a Strategic Communications Partner to Biotech & Money

London, UK: The Life Sciences team of Instinctif Partners, the international business communications consultancy, is pleased to announce that it has been elected as a strategic communications partner by  Biotech and Money, the new online members only community of senior level executives from the global biopharma industry. The partnership will enable Instinctif Partners to offer new communication opportunities to its life sciences clients and increase Biotech and Money’s access to the scientific and financial community.

Read more »

Forbion Announces Closing of Initial Public Offering of Portfolio Company arGEN-X

Naarden, The Netherlands - Forbion Capital Partners, the leading Dutch Venture Capital firm investing in world-class healthcare technologies, is proud to announce that its portfolio company arGEN-X N.V. (arGEN-X or the company), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, has successfully completed its Initial Public Offering, which was launched on 23 June 2014 (“IPO” or the “Offering”). arGEN-X shares will be listed on Euronext Brussels and begin trading on an “if-and-when-issued-or-delivered” basis  on Thursday 10 July 2014 under the symbol “ARGX”.

Read more »

Dezima Pharma extends clinical development program for its CETP Inhibitor TA-8995

Naarden, The Netherlands – Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, today announced the approval of a phase 1 pilot study in subjects with isolated, elevated Lipoprotein(a) (Lp(a)), for which additional funding has been secured.

Read more »

Xellia Pharmaceuticals Expands into the US with Acquisition of Manufacturing Plant

Copenhagen, Denmark – Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, today announced it has acquired Fresenius Kabi’s dedicated lyophilized (freeze-dried) vial manufacturing facility in Raleigh, North Carolina. The deal includes a continuous manufacturing and supply agreement with Fresenius Kabi USA. Financial details are not disclosed.

Read more »

Lesaffre Invests €10m into Seventure’s Health for Life Capital Fund Investment

Paris and Marcq-en-Baroeul, France – Seventure Partners, one of Europe’s leaders in financing innovation, today announces that Lesaffre, a French family group that set the global standard for yeasts and other fermentation products, has invested €10 million into its €120 million Health for Life Capital Fund, bringing the total raised current funds to €73.5 million (US$100m).

Read more »

Premaitha Looks to Deliver Diagnostic Test Product to Improve Prenatal Screening Globally

Manchester, UK — Today, Premaitha Health plc, located at the Manchester Science Park, UK has commenced trading on London Stock Exchange platform AIM.  The Company has raised £7.2m by way of Placing and an Open Offer (TIDM: NIPT) which will be used to commercialise the IONA® test.

Premaitha Health plc is a molecular diagnostics company employing next generation DNA analysis technology to develop molecular diagnostic products intended to have a major beneficial impact on human health.

Read more »

Source BioScience - Appointment to the Board

Nottingham, UK - Source BioScience plc (LSE: SBS) the international laboratory services and products business, announces that Pam Liversidge, OBE will join the Board as a Non-Executive Director with immediate effect.

Read more »

Nordic Life Science Days 2014, Stockholm 7-9 September

Stockholm - SwedenBIO, the Swedish Life Science Industry Organisation, Oslo Cancer Cluster, Toulouse Cancer-Bio-Santé Cluster and European Cancer Cluster Partnering, in conjunction with sister organisations in Denmark, Finland and Norway, invite you to attend the second Nordic Life Science Days event.
 

Read more »

Stage 3 Phase 2 Study of DARPin Abicipar Pegol (previously MP0112) Supports Progressing to Phase III Development Program

Zürich-Schlieren, Switzerland - Molecular Partners AG announced today results from the Allergan-sponsored, double-masked stage 3 phase 2 study of the DARPin abicipar pegol, for wet age-related macular degeneration (AMD).

Read more »

Prosensa Strengthens its Management Team and Supervisory Board with Key Appointments

Leiden, The Netherlands – Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced the appointment of Willem W. van Weperen to the new position of chief commercial officer and the addition of Dr. Annalisa Jenkins to its Supervisory Board.

Read more »

Prosensa Awarded $200,000 Research Grant from PPMD

LEIDEN, The Netherlands –  Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that Dr. Judith van Deutekom, Prosensa’s Vice President of Drug Discovery, has been awarded a $200,000 research grant from Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne Muscular Dystrophy (DMD), to fund the development of a multi exon-skipping strategy for exons 10-30 of the dystrophin gene.

Read more »

NovaBiotics’ Dr Deborah O’Neil Wins Entrepreneur of the Year

Aberdeen, UK – NovaBiotics Ltd, the Aberdeen-based, clinical-stage biotechnology company (“NovaBiotics” or the “Company”), today announced that CEO Dr Deborah O’Neil was last night awarded Entrepreneur of the Year Award at the 2014 Grampian Awards for Business Excellence at the Mercure Aberdeen Ardoe House Hotel in Aberdeen.

Read more »

Prosensa Completes Enrollment in Natural History Study of Duchenne Muscular Dystrophy

Leiden, The Netherlands - Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced the successful completion of enrollment in its prospective Natural History Study designed to increase the understanding of Duchenne muscular dystrophy (DMD).

Read more »

Initiation of a Phase IIa Clinical Study for Lynovex® in Cystic Fibrosis

Aberdeen, UK – NovaBiotics Ltd, the Aberdeen-based speciality biotechnology company (“NovaBiotics” or the “Company”), today announced the initiation of an open label/single arm Phase IIa clinical study to assess the safety, tolerability, pharmacokinetics and initial evidence of efficacy of orally-dosed Lynovex®.  The Phase IIa trial will be undertaken in collaboration with the University of Aberdeen and NHS Grampian.

Read more »

First successful exit in 2014 for Seventure Partners

Paris, France – Seventure Partners and co-investor Bpifrance have successfully sold AssurOne Group to AnaCap Financial Partners LLP (“AnaCap”), the specialist European financial services private equity firm and AssurOne’s management. AssurOne is a leading French digital insurance broker specialising in online distribution and management of personal insurance products, including motor and home policies. Seventure Partners and Bpifrance have supported the growth of the business since 2006 and 2008 respectively.

Read more »

Evaluate Ltd: Worldwide Prescription Drug Sales to Exceed Trillion Dollar Mark by 2020

London, UK, Boston and San Diego, US and Tokyo, Japan – Record breaking new drug approvals, a hefty product pipeline and dramatically improved R&D productivity that has kept expenditure growth below sales growth prove that the industry is turning a new corner according to Evaluate’s, “World Preview 2014, Outlook to 2020” report.

Read more »

Marks & Clerk: US Organisations Reaping Rewards of Public Investment in Genomic Research, with Europe and Asia Lagging Behind

London, UK and San Diego, CA, USA – Public research organisations are driving advances in research into genome-related technologies and their use in medicine and industry, with the private sector lagging behind, according to research by leading international intellectual property firm Marks & Clerk, released as part of its Life Sciences Report 2014: Genome 2.0, today at the BIO International Convention 2014 in San Diego. The research further highlights the global disparity, with the advantage almost entirely enjoyed by the US, whilst Europe and Asia trail behind, despite over €1 billion of public funding coming from the EU for research into personalised medicine between 2007 and 2012.

Read more »

CytoTools AG Adds Cardiovascular and Further Indications to Its Field of Interest Following Capital Increase at CytoTools Subsidiary CytoPharma GmbH

Darmstadt, Germany – The Shareholders’ Meeting of CytoPharma GmbH has unanimously approved a capital increase totalling around EUR 1.7 million. The capital has been provided by two existing shareholders and by new shareholders. CytoTools AG participated in this round with approximately EUR 0.3 million, thus maintaining its stake in CytoPharma GmbH at significantly above 40%. The additional liquidity will enable CytoTools AG to continue to support the successful research activities at this subsidiary. It will begin to plan implementation of its existing cardiovascular research pipeline in initial clinical studies.

Read more »

Clinigen Group’s Peter George Wins Chief Executive of the Year Award

Burton-on-Trent, UK – Clinigen Group (AIM: CLIN), the specialty global pharmaceutical company, has announced that CEO Peter George won the Chief Executive of the Year Award at last night’s 2014 European Mediscience Awards.

Read more »

Instinctif Partners Congratulates John Carroll for Winning “Mediscience Commentator of the Year” Award

London: Instinctif Partners is pleased to congratulate John Carroll from FierceBiotech for winning the 2014 award for the “Mediscience Commentator of the Year” at the European Mediscience Awards on 19th June 2014 in recognition of his clear and concise commentary on the Life Sciences Sector.

Read more »

NovaBiotics’ Dr Deborah O’Neil Named EY Scotland Entrepreneur of 2014

Aberdeen, UK –  NovaBiotics Ltd, the Aberdeen-based, clinical-stage biotechnology company (“NovaBiotics” or the “Company”), today announced that Dr. Deborah O’Neil, the Company’s Chief Executive Officer, was named an EY Scotland Entrepreneur of the Year 2014 at the awards dinner held at The Gleneagles Hotel in Perthshire, Scotland last night.

Read more »

Big Pharma Becomes a Smaller Employer While Biotech Booms

London, Boston, Tokyo – Big pharma employment dropped by 3 percent in the decade 2003-2013, allaying fears that industry consolidation and restructuring would lead to significantly reduced headcounts and payrolls, a new jobs report published by EP Vantage reveals.

Read more »

Novogen and CanTx Announce Potency of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant Ovarian Cancer Stem Cells

Boston,MA – Australian oncology drug development company Novogen Limited [ASX:NRT; NASDAQ:NVGN] and CanTx Inc., its joint venture with Yale University, today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity.

Read more »

Portfolio company Abzena announces intention to float

London, UK - Imperial Innovations Group plc (AIM: IVO or ‘the Group’ ‘Innovations’) notes that Abzena Limited (‘Abzena’), formerly known as PolyTherics, has today announced its intention to proceed with an initial public offering and to seek Admission of its shares to AIM.

Read more »

NOXXON Presents Updates on Phase II Studies with Olaptesed Pegol (NOX-A12) in CLL and MM and Lexaptepid Pegol (NOX H94) in Anemic Cancer Patients

Berlin, Germany – NOXXON Pharma presented updated interim data sets from two independent clinical Phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer® olaptesed pegol (NOX-A12) and the outcome of a Phase IIa pilot study on the anti-hepcidin Spiegelmer® lexaptepid pegol (NOX-H94) for treating anemia of chronic diseases at the 19th Congress of the European Hematology Association (EHA) in Milan, Italy, from 12-15 June 2014.

Read more »

Source BioScience plc: Annual General Meeting Statement

Nottingham, UK − Laurie Turnbull, Chairman of Source BioScience, will be making the following comments at the 2014 Annual General Meeting to be held today at 10.30am:
“Since our last Annual General Meeting, twelve months ago, the Group has undergone a period of major transformation and the acquisitions made during 2013 have created significant opportunities, particularly for the second half of 2014.  The Group continues to trade in line with management’s expectations for the full year.

Read more »

Senior Team Members in Life Sciences Promoted to Associate Partner, Join the Global Partnership Senior Team

London and Manchester, UK:  Instinctif Partners has announced the promotion of Dr Christelle Kerouedan and Dr Eileen Paul in its Life Sciences team.  Both Christelle and Eileen become Associate Partners and join the global partnership forum.

Read more »

Autifony Therapeutics Awarded £2.2 million to Progress First-In-Class Drug for Tinnitus into Phase IIa Study

London, UK – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has been awarded funding of £2.2 million towards a Phase IIa clinical trial in tinnitus patients with its lead compound AUT00063, by the UK’s innovation agency, the Technology Strategy Board. Autifony will be sponsor of the clinical study, with Professor Deborah Hall at The University of Nottingham and National Institute for Health Research (NIHR) Nottingham Hearing Biomedical Research Unit (BRU) as lead academic collaborator.

Read more »

Imperial Innovations Group plc: Autifony Receives Funding from Technology Strategy Board for Phase II Clinical Trial in Tinnitus

London, UK - Imperial Innovations Group plc (AIM: IVO, "Innovations", “the Group”) is pleased to note that its portfolio company Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, has today announced that it has been awarded funding of £2.2 million, in the form of a grant, from the Technology Strategy Board (TSB).

Read more »

Prosensa Announces Regulatory Path Forward for Drisapersen as a Potential Treatment for DMD

Leiden, The Netherlands – Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced that the United States Food and Drug Administration (FDA) has outlined a regulatory path forward, under an accelerated approval pathway, for drisapersen, the Company’s lead program for the potential treatment of Duchenne Muscular Dystrophy (DMD). In addition, the company has been interacting with the European Medicines Agency (EMA) and based on these interactions intends to file in Europe as well.

Read more »

NOXXON’s Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference

Berlin, Germany  – NOXXON Pharma AG announced that Prof. Hermann Haller, Director of the Department of Nephrology and Hypertension at Hannover Medical School, was invited in his role as the principal investigator to present the full data of NOXXON’s phase IIa clinical trial with emapticap pegol (NOX-E36), for the treatment of diabetic nephropathy during the 2014 congress of the European Renal Association and the European Dialysis and Transplant Association.

Read more »

Nanobiotix Presents Successful Phase I Results for its Lead Nanomedicine Product NBTXR3 at ASCO

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced the successful completion of the first in human study of its lead NanoXray product, NBTXR3, which will be presented today at the American Society of Clinical Oncology (ASCO) annual meeting.

Read more »

Imperial Innovations plc: Peter Chambré and Linda Wilding Appointed as Non-Executive Directors

London, UK – Imperial Innovations Group plc (AIM: IVO, “Innovations”), has appointed Peter Chambré and Linda Wilding to the Board as non-executive directors. Their appointments are conditional upon the passing of the resolution to adopt new articles of association at the forthcoming General Meeting on 19 June 2014, thereby removing provisions in the existing articles relating to the maximum number of directors that may be appointed by Innovations. Their appointments will become effective immediately following the passing of the resolution.

Read more »

Imperial Innovations Group plc: Proposed Placing to Raise Up to £150 million

London, UK –  Imperial Innovations Group plc (AIM: IVO, "Innovations") is proposing to raise up to £150 million (before expenses) by way of a non-pre-emptive placing of new Ordinary Shares with existing and new institutional investors (the "Placing"). The Placing and its timetable are subject to a number of factors, including prevailing market conditions and execution of definitive documentation.  It is also subject to the passing of Placing Resolutions by Shareholders at a general meeting of Shareholders to be held on 19 June 2014.

Read more »

Cerenis Reports Two Positive Phase II Studies for HDL Mimetic CER-001 at EAS

Toulouse, France and Ann Arbor, Michigan, US – Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan  Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.

Read more »

Novogen Identifies Highly Active Drug Candidates Against Prostate Cancer

Sydey, Australia — Novogen Limited [NASDAQ:NVGN, ASX:NRT], an oncology drug development company, today announced that it has achieved a key milestone with its super-benzopyran (SBP) drug program, having identified a number of SBP compounds with potent anti-cancer activity against human prostate cancer cells in vitro. As a result, Novogen has extended its preclinical SBP program to include prostate cancer as well as ovarian and brain cancers.

Read more »

Auven Therapeutics and BELLUS Health Announce Completion or Enrollment in the Phase III Confirmatory Study of KIACTA™ for the Treatment of AA Amyloidosis

New York, USA and Laval, Canada – Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and BELLUS Health Inc. (TSX:BLU), a drug development company focused on rare diseases, today announced that the KIACTA™ Phase III Confirmatory Study in AA amyloidosis (an orphan indication) has completed its targeted enrollment of 230 patients. Eligible patients currently in screening will also be given the opportunity to enroll in the study likely increasing total recruitment beyond 230 patients.

Read more »

Instinctif Partners Congratulates the Nominees for the European Mediscience Awards 2014

22 May 2014, London: Instinctif Life Sciences (formerly College Hill) congratulates all the nominees shortlisted for the European Mediscience Awards 2014, especially those individuals and companies in the category, Commentator of the Year, of which Instinctif Partners is the sponsor.

Read more »

Prosensa Announces 1st Quarter 2014 Financial Results and Recent Corporate Developments

LEIDEN, The Netherlands — Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported financial results for the first quarter ending March 31, 2014 and provided an update on the next steps for its exon-skipping platform for the treatment of Duchenne Muscular Dystrophy (DMD).

Read more »

Source BioScience - Interim Management Statement

Source BioScience plc (LSE: SBS), the international laboratory services and products business, today publishes its Interim Management Statement for the year to date. Unless otherwise stated, the financial information referenced below refers to the period ended 31 March 2014 and the corresponding period last year.
 

Read more »

ADC Therapeutics to Move ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials with Partner MedImmune

Lausanne, Switzerland and London, UK – ADC Therapeutics (ADCT), an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, announced today that it has selected its first IND candidate under its joint development agreement with MedImmune, the global biologics research and development arm of AstraZeneca.
This follows the October 2013 announcement in which MedImmune entered into a collaboration agreement with ADC Therapeutics to jointly develop two of ADCT’s antibody-drug conjugate programs in preclinical development.

Read more »

Telormedix’s Vesimune Successfully Completes Phase II for Carcinoma In Situ of the Bladder

Bioggio, Switzerland - Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has successfully completed a Phase II trial, conducted under an IND, of Vesimune (TMX-101) in CIS (carcinoma in situ) of the bladder.

Read more »

Xellia Pharmaceuticals Expands Croatian Product and Innovation R&D Centre of Excellence with Investment of US$2.0 million

Copenhagen, Denmark and Zagreb, Croatia -  Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, today announced that it has invested US$2.0 million (around HRK11.5 million) to significantly expand its Product and Innovation R&D Centre of Excellence in Zagreb, Croatia. This development is part of the Company’s continuing investment in Croatia and represents the latest stage of Xellia’s on-going global expansion plans.

Read more »

BioSpring Selects GE Healthcare Life Sciences OligoProcess™ for Large Scale Synthesis of Therapeutic Oligonucleotides

Chalfont St. Giles, UK and Frankfurt, Germany – GE Healthcare Life Sciences (NYSE: GE) and German oligonucleotide manufacturer BioSpring GmbH announced today that BioSpring has selected and installed GE Healthcare Life Sciences’ OligoProcess, a fully automated oligonucleotide synthesizer, as a core element of its state-of-the-art production facility in Frankfurt.

Read more »

Nanobiotix Revenue for the 1st Quarter of 2014 and new composition of the shareholding

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the first quarter of 2014 and presents the new breakdown of its share capital pursuant to the capital increase with preferential subscription rights completed in March 2014.

Read more »

e-Therapeutics’ full year results for the 12 months ended 31 January 2014

Oxford and Newcastle, UK - e-Therapeutics plc (AIM: ETX), the drug discovery and development company, today announces its full year results for the 12 months ended 31 January 2014.

Read more »

e-Therapeutics Announces Recruitment Resumes into US phase I ETS2101 Brain Cancer Trial

Oxford and Newcastle, UK – e-Therapeutics plc (AIM:ETX) announces today that the US Food and Drug Administration (FDA) has approved the resumption of recruitment of new patients into the Company’s investigator-led Phase Ia study of ETS2101 in brain cancer, conducted at the University of California San Diego Moores Cancer Centre.

Read more »

Scil Proteins Announces New Management Team and Revised Focus

Halle, Germany – Scil Proteins, the expert company in Affilin®-based protein engineering, today announced that Dr Henning Afflerbach has been appointed as chief executive officer (CEO) and Dr Ulrich Haupts is named managing director, in addition to his current role as chief scientific officer (CSO).

Read more »

Auven Therapeutics and Bellus Health Announce Engagement of Financial Advisor to Explore Sale of KIACTA™, an Experimental Drug in Phase III Development for the Treatment of AA Amyloidosis

New York, USA and LAVAL, CANADA – Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and BELLUS Health Inc. (TSX:BLU), a drug development company focused on rare diseases, today announced that Lazard has been engaged as financial advisors to explore the sale of KIACTA™, an orphan drug nearing completion of its confirmatory Phase III trial as a treatment for AA Amyloidosis.  Auven and BELLUS Health also have amended the asset purchase and license agreement related to KIACTA™ (eprodisate disodium) in order to facilitate a potential sale of KIACTA™.

Read more »

Apitope Initiates Preclinical Development of Peptide Therapy,ATX-F8-117, to Treat Factor VIII Intolerance

Diepenbeek, Belgium – Apitope, a drug discovery and development company focused on disease-modifying peptide treatments for the underlying cause of autoimmune and allergic diseases, announced today that its peptide therapy for the treatment of Factor VIII intolerance, ATX-F8-117, has formally entered preclinical development.

Read more »

Pantec Biosolutions Announces Research Agreement with Takeda to Investigate New Approaches for Inflammatory Skin Disease

Ruggell, Liechtenstein – Pantec Biosolutions AG, the manufacturer of P.L.E.A.S.E.® Professional, a portable laser device for the precise microporation of the skin, has signed a research agreement with the New Frontier Science group at Takeda Pharmaceutical Company, Ltd. for the development of potential new treatments for inflammatory skin disease.

Read more »

Novogen: Children’s Oncology Drug Alliance (CODA) Formed to Facilitate Development of Treatments for Childhood Cancers

Sydney, Australia and Columbus, US – Researchers and children’s cancer advocates in Australia and the U.S. have formed a unique research and development alliance to facilitate development of treatments for children fighting neuroblastoma, the most common and fatal form of solid cancer affecting infants.

Read more »

Novogen Presentation at Cavendish Global Impact Forum Available Online

Sydney - Novogen Limited (ASX: NRT; NASDAQ: NVGN) an oncology drug development company is presenting today at the Cavendish Global Impact Forum at the United Nations Headquarters in New York.

Read more »

Auven Therapeutics and BELLUS Health Announce Licence Agreement with Mount Sinai for KIACTATM in Sarcoidosis

New York, USA and Laval, Canada – Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and Bellus Health Inc. (TSX: BLU), a drug development company focused on rare diseases, today announced that Auven has entered into a license agreement with the Icahn School of Medicine at Mount Sinai in New York, under which Auven obtains rights to develop KIACTA™ (eprodisate) as a treatment for chronic sarcoidosis.

Read more »

Novogen and Genea Announce Partnership to Investigate Promising New Approach to Neurodegenerative Diseases

Sydney, Australia - Novogen Limited (NASDAQ: ‘NVGN’, ASX: ‘NRT’;), an oncology drug development company, today announced a collaboration with Australian company, Genea Biocells, to accelerate testing of their super-benzopyran (SBP) drugs for degenerative diseases of the nervous system and muscles.

Read more »

Fibrotech acquired by Shire for US$75M plus milestones

Melbourne, Australia – Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that it has reached an agreement with Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, under which Shire has agreed to purchase Fibrotech for an upfront payment of $75M and certain contingent payments based on the achievement of development and regulatory milestones.

Read more »

Sovaldi Forecast to be Biggest Selling Drug in 2020 as EvaluatePharma Extends Consensus Sales Forecasts

LONDON, BOSTON, TOKYO – Life science market intelligence company, Evaluate, Ltd., announced today that it has extended its exclusive consensus sales forecast analyses within its service platforms from 2018 to 2020. Evaluate’s consensus forecasts are derived by its expert analysts using the un-weighted average of up to six of the leading equity research forecasts.

Read more »

Prosensa Provides Update on Drisapersen

Leiden, The Netherlands - Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, yesterday provided the data analysis of its second open-label extension study (DEMAND IV/DMD114349) of drisapersen in boys with Duchenne Muscular Dystrophy (DMD) during the 66th American Academy of Neurology (AAN) Annual Meeting in Philadelphia, PA. 

Read more »

Life Sciences Team Promotions and Updates at Instinctif Partners

London and Manchester, UK – International business communications consultancy Instinctif Partners has announced the promotions and job progression of three of its Life Sciences team members in London and Manchester.

Read more »

Seventure Partners’ Health for Life Capital Fund Makes First Investments

Paris, France – French portfolio companies Enterome Bioscience SA (“Enterome”) and Laboratoires Nutrition & Cardiométabolisme (“LNC”) have received the inaugural investments from Seventure Partners’ (“Seventure’s”) new €120m Health for Life Capital fund, which was launched in December 2013.

Read more »

GE Healthcare Life Sciences and Promosome sign licensing agreement

Chalfont St. Giles, UK and New York, USA – GE Healthcare Life Sciences, (NYSE: GE), and Promosome LLC announced today that the companies have signed a licensing agreement, granting GE Healthcare exclusive rights to an innovative suite of  mammalian cell line development technologies, developed by Promosome, for increasing protein expression in mammalian cell culture.  Under the terms of agreement, Promosome will receive milestone payments for technology transfer and subsequent royalties upon commercialization.

Read more »

e-Therapeutics plc (AIM: ETX) Notification of Full Year Results Date

Oxford and Newcastle, UK – e-Therapeutics plc (AIM: ETX), the drug discovery and development company with a proprietary platform in network pharmacology, will be announcing its full year results for the period ended 31 January 2014 on Monday, 12 May 2014.

Read more »

NovaBiotics Shortlisted for the Grampian Award for Innovation

Aberdeen, UK – NovaBiotics Ltd, the Aberdeen-based, clinical-stage biotechnology company (“NovaBiotics” or the “Company”), today announced it has been shortlisted for The Grampian Award for Innovation at the 2014 Grampian Awards for Business Excellence which will be held on the 26th of June at the Mercure Aberdeen Ardoe House Hotel.

Read more »

Clinigen Group to Manage International Named Patient Program for Abiogen Pharma’s Nerixia® (Neridronic Acid)

Burton-on-Trent, UK and Pisa, Italy – Clinigen Group plc (‘Clinigen’ or the ‘Group’) (AIM: CLIN) and Abiogen Pharma SpA (‘Abiogen’) jointly announced today the initiation of a Named Patient Program, managed by Clinigen Global Access Programs (Clinigen GAP) to provide Nerixia® (neridronic acid), owned by Abiogen to individual patients with Osteogenesis imperfecta (OI) through their Healthcare Professional.

Read more »

Intercept Reports Additional Positive Data From POISE Trial at EASL Late-Breaker Session

New York, USA – Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) today announced efficacy and safety results from the Phase 3 POISE trial of obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBC) to be presented in a late-breaker session at the International Liver Congress of the European Association for the Study of the Liver (EASL). OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR) in development for PBC, nonalcoholic steatohepatitis (NASH) and other liver and intestinal diseases.

Read more »

Anti-Hepcidin Spiegelmer® Lexaptepid Pegol Increases Hemoglobin in Subset of Anemic Patients in Pilot Phase IIa Study

Berlin, Germany - NOXXON Pharma announced that data from a Phase IIa pilot study in anemic cancer patients treated with lexaptepid pegol (NOX-H94) will be presented today at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, CA.

Read more »

Prosensa to Appoint Michael Wyzga to Supervisory Board

Leiden, The Netherlands –  Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced that Michael S. Wyzga has been nominated for appointment to its Supervisory Board at the next shareholders’ meeting, scheduled for June 17, 2014.

Read more »

e-Therapeutics Announces That Steve Medlicott Has Been Appointed Finance Director

Oxford and Newcastle, UK – e-Therapeutics plc (AIM: ETX) announces today that Steve Medlicott has joined the Company as Finance Director.

Read more »

e-Therapeutics Announces Directorate Change

Oxford and Newcastle, UK – e-Therapeutics plc (AIM:ETX) announces that Dr Daniel Elger has resigned as Chief Financial Officer and a Director of e-Therapeutics plc with immediate effect. The Board thanks Dr Elger for his notable contributions to the Company and wishes him the best of luck with future ventures.

Read more »

NOXXON presents Positive Results from Emapticap Pegol Phase IIa Diabetic Nephropathy Study

Berlin, Germany  – NOXXON Pharma AG announced that Phase IIa proof-of-concept data from the emapticap pegol (NOX-E36) trial in diabetic nephropathy were presented at the ISN Nexus Symposium in Bergamo, Italy earlier today.

Read more »

Synthon’s Anti-HER2 ADC Frontrunner SYD985 Outperforms Only Available HER2-targeting ADC

Nijmegen, Netherlands – Synthon Biopharmaceuticals today announced the results of a head-to-head comparative program of its antibody-drug conjugate (ADC) SYD985 with Roche’s market leading anti-HER2 ADC, T-DM1 ( Kadcyla®).

Read more »

Nanobiotix Selected to Present Data from NBTXR3 Clinical Trial at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)

Paris, France – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has been selected by the American Society of Clinical Oncology (ASCO) to present data from its clinical trial evaluating NBTXR3 in advanced soft tissue sarcoma.

Read more »

Source BioScience Launches its Products and Services in the USA – Facilities in Los Angeles and Atlanta

Los Angeles and Atlanta, US - Source BioScience plc (LSE: SBS), the international laboratory services and products business, today announces the launch of its US business operating out of facilities in Los Angeles and Atlanta.  The Company will hold a ribbon cutting ceremony today at its Los Angeles site to celebrate the launch.

Read more »

Hookipa Biotech Wins Best Financing Deal Award in the Vaccine Industry Excellence (ViE) Awards 2014

Vienna, Austria – Hookipa Biotech AG, a company pioneering a new class of vaccines, is pleased to announce that it was the winner of the Best Financing Deal Award in the Vaccine Industry Excellence (ViE) Awards 2014, as part of VaccineNation and the World Vaccine Congress in Washington D.C. last week.

Read more »

e-Therapeutics Reports Positive Interim Results From UK Phase Ia Trial of ETS2101 (Dexanabinol) in a Variety of Solid Tumours

Oxford and Newcastle, UK – e-Therapeutics plc (AIM: ETX) announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.

Read more »

Clinigen Group Acquires Oncology Support Therapy SAVENE® (dexrazoxane) from SpePharm AG

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’) (LSE: CLIN) (AIM: CLIN) the specialty global pharmaceutical company today announces the acquisition of SAVENE® (dexrazoxane) from SpePharm AG, a majority owned affiliate of Norgine B.V. The financial terms of the acquisition are not being disclosed.

Read more »

Circassia IPO drives jump in profits as portfolio matures

London, UK - Imperial Innovations Group plc (AIM: IVO, “Innovations”, “the Group”), a leading technology investment group, has published its results for the six months ended 31 January 2014.

Read more »

Synthon Announces Successful Outcome of the Phase III GATE Study with its generic Glatiramer Acetate

Nijmegen, the Netherlands – Synthon today announced that the company’s glatiramer acetate met the main endpoint of a late-stage study in patients with relapsing remitting multiple sclerosis (RRMS). The Phase III Glatiramer Acetate clinical trial To assess Equivalence with Copaxone®* (GATE) is to-date the only Phase III study conducted with a generic version of Copaxone® and has demonstrated an equivalent efficacy and safety profile for Synthon’s glatiramer acetate compared to Copaxone®.

Read more »

e-Therapeutics Announces Recruitment Resumes into UK Phase I ETS2101 Cancer Trial

Oxford and Newcastle, UK – e-Therapeutics plc (AIM:ETX) announces today that it has received approval from MHRA to recommence recruitment of new patients into its ETS2101 phase Ia solid tumours trial being conducted at three centres in the UK.

Read more »

Instinctif Partners extends Life Sciences Public Policy expertise into Germany

 

Instinctif Partners has built an impressive Public Policy offering with notable expertise in pharma and medtech across its teams in the UK (London) and the EU (Brussels).  With the acquisition of Brand Associates, this experience is extended to Germany (Berlin).  Brand’s clients in the Life Sciences sector include Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lilly Deutschland and PhRMA. Read more

Read more »

Global Bioenergies: Key Patents Granted in First Country

Evry, France – Global Bioenergies (NYSE Alternext Paris: ALGBE) announces that the Australian Intellectual Property Office has granted two patents that protect key steps of its process for converting renewable resources into isobutene.

Read more »

Prosensa Announces Full Year 2013 Financial Results and Recent Corporate Developments

Leiden, The Netherlands — Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported financial results for the full year ending December 31, 2013, and provided an update on the next steps for its exon-skipping platform for the treatment of Duchenne Muscular Dystrophy (DMD).

Read more »

Novogen and CanTx Experimental Drug, Trx-1, Proves Effective in Vivo

Sydney, Australia  -  Novogen Limited [ASX:NRT; NASDAQ:NVGN] and its joint venture company with Yale University, CanTx Inc, today announced an important milestone with lead candidate drug, Trx-1, demonstrating a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells.

Read more »

Preliminary Results for the Year Ended 31 December 2013

Nottingham, UK - Source BioScience plc (LSE: SBS), the international laboratory services and products business announces its unaudited preliminary results for the year ended 31 December 2013.

Read more »

Clinigen Group Reports Pan European Lifting of Marketing Authorization Suspension for VIBATIV® (telavancin)

Burton-on-Trent, UK – Clinigen Group plc (‘Clinigen’ or the ‘Group’) (AIM: CLIN) today announced that the European Commission (EC) has ratified the positive opinion in January 2014 from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) to lift the Europe-wide suspension of Marketing Authorization for VIBATIV® (telavancin).

Read more »

Prosensa Announces 48-Week Data from a U.S. Phase II Placebo-Controlled Study of Drisapersen in 51 DMD Boys

Chicago, IL — Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported encouraging 48-week  data from its U.S.-based, Phase II placebo-controlled study (DMD114876 or DEMAND V) of its lead compound, drisapersen, for the treatment of Duchenne Muscular Dystrophy (DMD).

Read more »

Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York

Sydney, Australia – Novogen Limited (ASX:NRT; NASDAQ:NVGN), an oncology drug development company, today announced that Graham Kelly, Ph.D., Executive Director and Chief Executive Officer, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum. Dr. Kelly’s presentation will take place at 2:30 p.m. on Wednesday, March 19, 2014 at the New York Academy of Sciences in New York City.

Read more »

Spectacular Images Showing Research into Cancer, Neurodegenerative Disease and Fertility Win GE Healthcare 2013 Cell Imaging Competition

Chalfont St. Giles, UK – GE Healthcare Life Sciences (NYSE:GE) today announced Vanessa Auld from Canada, Martin Barr from Ireland and Graham Wright from Singapore as the winners of the GE Healthcare 2013 Cell Imaging Competition.   With over 23,000 votes cast by the public, the winners can now look forward to seeing their prize-winning images lighting up Times Square, New York at a special event between 25-27 April 2014.

Read more »

Novogen Selected to Present at Cavendish Global Health Impact Forum

Sydney, Australia — Novogen Limited (ASX: ‘NRT’; NASDAQ: ‘NVGN’), an oncology drug development company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 at the United Nations Headquarters in New York.

Read more »

M&A Slowdown and Drop in FDA Approvals Stifles Growth of Medtech Sector in 2013

London, UK, Boston, US and Tokyo, Japan –  At the half-year mark, the medtech sector was on course for its worst year in a decade in terms of M&A activity, EP Vantage concluded last fall in its Half Year Review 2013 report. Unfortunately, the second half of the year showed little sign of improvement, according to EP Vantage’s latest report on the sector, “Medtech 2013 in Review.”

Read more »

Evaluate Ltd: Record-Breaking Valuations and Surging Share Prices Drive Strong Pharma and Biotech Sector Performance in 2013

London, UK, Boston, US and Tokyo, Japan –  The cautious optimism of 2012 turned into a fully fledged biotech boom in 2013, marked by surging company valuations in the US and the opening of the IPO floodgates. The pharma and biotech sector also saw an increase in M&A deal values, buoyant licensing activity and sustained venture capital investment last year, according to EP Vantage’s latest report, “Pharma & Biotech 2013 in Review.”

Read more »

Fibrotech Announces Positive Phase Ia Results for Anti-fibrotic FT011

Melbourne, Australia – Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that its lead anti-fibrotic compound FT011 has successfully completed a Phase Ia trial in healthy volunteers demonstrating safety and tolerability up to doses of 1000mg. At the same time Fibrotech announced the commencement of a Phase Ib trial involving patients with diabetic nephropathy associated with Type 1 or Type 2 diabetes. Both trials have been and will be conducted in Australia.

Read more »

Clinical Network Services (CNS) Opens New UK Office and Expands Core Services

Brisbane, Australia - Clinical Network Services (CNS) an integrated product development company based in Australia and New Zealand providing broad services in the planning, implementation and delivery of preclinical, Phase 1 and 2 trials, today announced that it has launched a new office near London headed by Paul Cronin who joins as UK Director and Director, Business Development.  The new UK office is primarily a BioDesk initiative and CNS will continue to undertake its core business of conducting early phase clinical trials in Australian & New Zealand given the simplicity of regulatory review and time advantages for this region.
At the same time the Company has launched a new Biometrics service and has appointed Otto Damsma as Director of Biometrics and Glynn Morrish as Pharmacometrician/Biostatistician at its Brisbane headquarters.

Read more »

Novogen Appoints New Board Members and Strategic Advisor to Support Transition to Clinical Development and Growing International Presence

Sydney, Australia −  Novogen Limited (ASX:NRT; NASDAQ:NVGN]), an oncology drug development company, today announced key new appointments to guide the company in its transition into a clinical-stage company with a growing U.S. presence and an investor base in the U.S. and Australia. Professor Peter Gunning, PhD, a leading world authority on the cytoskeleton, and Iain Ross, an experienced multi-national pharmaceutical and biotechnology executive, join the Novogen board of directors as non-executive directors. David W. Gryska, an industry expert with over 20 years of experience in management at many of the top U.S. biotechnology companies, will serve as a strategic advisor to the board with a focus on U.S. capital markets and as a U.S. shareholder liaison.

Read more »

OGT Expands Leadership in Genomic Medicine with Acquisition of Cytocell Ltd

Oxford and Cambridge, UK –  Oxford Gene Technology (OGT), a provider of innovative genetics research solutions, today announced the acquisition of Cambridge-based Cytocell Limited (Cytocell), a leading provider of DNA technology for the detection of gene rearrangements related to inherited genetic disease and cancer.

Read more »

Fibrotech is Granted US and Canadian Patents for its Anti-fibrotic Compounds

Melbourne, Australia – Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that it has been granted patents in the USA and Canada relating to the Company’s proprietary novel anti-fibrotic compounds.
The US patent is entitled “Halogenated Analogues of Anti-Fibrotic Agents” and the Canadian patent is entitled “Therapeutic Compounds”. Both have been granted composition of matter claims.

Read more »

Clinigen Group plc Announces Half Year Results for the Six Months Ended 31 December 2013

Burton-on-Trent, UK – Clinigen Group plc (AIM: CLIN, Clinigen or the Group), the global specialty pharmaceuticals and pharmaceutical services business, has today published its half year results for the six months ended 31 December 2013.

Read more »

Cancer Therapeutics Cooperative Research Centre (CTx) Successful in Application for Further Funding

Melbourne, Australia – Cancer Therapeutics CRC (CTx) is pleased to announce that the Cooperative Research Centres (CRC) Program has agreed to continue their funding for a further six years.

Read more »

Forbion Announces Closing of Public Offering of Portfolio Company, Argos Therapeutics

Naarden, The Netherlands – Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, announces that its portfolio company Argos Therapeutics (“Argos” or “the Company”) has closed its initial public offering.

Read more »

Instinctif Partners sponsors the European Mediscience Awards Event for the 6th year

London, UK: Instinctif Partners (formerly College Hill) announces that it is the sponsor for the "Mediscience Commentator of the Year" at the European Mediscience Awards on 19 June 2014.  This will be the 6th year Instinctif Partners has sponsored the awards.

Read more »

SynAffix Raises Series A Investment Round to Advance its GlycoConnect™ Technology for Creating Next-Generation ADCs

Oss, The Netherlands –  SynAffix B.V., a protein engineering company focusing on the creation of next-generation Antibody-Drug Conjugates (ADCs), today announced the completion of its Series A investment round. Financial details have not been disclosed.

Read more »

Stroke Patients With Swallowing Problems Show Improved Recovery With New Treatment, Study Shows

Manchester, UK – Stroke patients with the inability to swallow safely (dysphagia) show improved and faster recovery in their swallowing function when using pharyngeal electrical stimulation (PES) versus sham treatment at three months, according to data published as part of the paper: Dysphagia Diagnosis and Treatment: A Multidisciplinary Challenge in the journal Dysphagia.

Read more »

Forbion Announces Closing of Initial Public Offering of Portfolio Company uniQure

Naarden, The Netherlands – Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, is proud to announce that its portfolio company uniQure N.V. (uniQure or the company) has closed its initial public offering of ordinary shares at an initial public offering price of $17.00 per ordinary share.

Read more »

e-Therapeutics Begins Phase I Study of Oral Formulation of Anti-Cancer Compound ETS2101 with Healthy Volunteers

Oxford and Newcastle, UK – e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101.

Read more »

NovaBiotics Wins Life Science Business Leadership Award

Aberdeen, UK –  NovaBiotics Ltd, the Aberdeen-based, clinical-stage biotechnology company (“NovaBiotics” or the “Company”), today announced that it was awarded the Life Science Business Leadership Award at the Scottish Enterprise Life Sciences Annual Dinner last night at the Edinburgh International Conference Centre.

Read more »

Circassia announces intention to float

London, UK — Imperial Innovations Group plc (AIM: IVO, "Innovations", “the Group”) is pleased to note that its largest portfolio company Circassia, has today announced its Intention to Float on the London Stock Exchange’s Main Market.

Read more »

Evaluate Ltd: Absence of Blockbuster Drug Launches in 2014 Puts R&D Productivity at Risk

London, UK, Boston, USA and Tokyo, Japan — The past two years have brought a surge of R&D productivity, driving investor confidence and increasing market performance, but 2014 looks to tell a different tale according to the new report, “Biggest Launches 2014,” from EP Vantage.

Read more »

Novogen Announces Key Appointments to Drive Development of Anti-Tropomyosin Drug Platform

Sydney, Australia – Novogen Limited (ASX:NRT; NASDAQ:NVGN), an oncology drug development company, today announced the appointments of Justine Stehn, PhD and Professor Peter Gunning, PhD to roles within the Company. Dr. Stehn and Professor Gunning are the co-inventors of the anti-tropomyosin (ATM) drug technology platform that Novogen acquired in 2013, and their appointments are an important step in realizing the significant potential of this new drug platform in treating cancer.

Read more »

College Group rebrands as Instinctif Partners

College Group (including leading brands College Hill, The College, College Public Policy, Policy Action, Green Issues Communique, Stockheim Media and Instinctif) is rebranding and unifying its business operations under one single brand – Instinctif Partners.

We have also moved to our new London headquarters at 65 Gresham Street, London, EC2V 7NQ.

Read more »

College Group to rebrand as Instinctif Partners

Global business communications consultancy, College Group (including leading brands College Hill, The College, College Public Policy, Policy Action, Green Issues Communique, Stockheim Media and Instinctif) announces that it is today rebranding and unifying its business operations under one single brand – Instinctif Partners.

Read more »

e-Therapeutics announces temporary halt of recruitment into ETS2101 cancer trials because of drug supply issue

Oxford and Newcastle, UK – e-Therapeutics plc (AIM:ETX) today announces that recruitment of patients into both of the ongoing phase I trials of ETS2101 has been halted temporarily because of a practical issue with stored drug for the trials. Patients already receiving treatment with ETS2101 will continue to be dosed in accordance with trial protocols. Relevant regulators are being notified and the Company is taking steps to enable recruitment to resume as soon as possible.

Read more »

Nanotherapeutics selects GE Healthcare Life Sciences technologies for Advanced Development and Manufacturing Center

Chalfont St. Giles, UK – GE Healthcare (NYSE:GE), today announced that biopharmaceutical company Nanotherapeutics, Inc. has selected GE Healthcare Life Sciences' FlexFactory™ biomanufacturing platform to perform a central role in its Advanced Development and Manufacturing (NANO-ADM) Center at Alachua, Florida, USA.  Construction of the NANO-ADM Center, which began in October 2013, is expected to be complete in early 2015.

Read more »

GLOBAL BIOENERGIES partners with AUDI on drop-in biofuel

Evry, France and Ingolstadt, Germany – Global Bioenergies announces the signature of a collaboration with the German car-manufacturer Audi on the development of isobutene-derived isooctane, a high performance biofuel for gasoline engines.
 

Read more »

Seventure Partners Launches New €120m ‘Health For Life Capital’ Innovation Fund

Paris, France – Seventure Partners, one of Europe’s leaders in innovation financing, has announced the launch of its new fund: Health for Life Capital.

Read more »

Imugene Appoints Distinguished Scientists to Scientific Advisory Board

Melbourne, Australia – Australian biopharmaceutical company Imugene (ASX;IMU) today announced the appointment of Univ. Professor Dr Dr.h.c. Christoph Zielinski and Univ. Professor Dr Ursula Wiedermann MD, PhD, to the Company's Scientific Advisory Board.

Read more »

Prosensa Reports Initial Findings from the Further Clinical Data Analyses of Drisapersen for the Treatment of Duchenne Muscular Dystrophy

Leiden, The Netherlands – Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet medical need, today announced initial findings from further analyses from the aggregate data from the clinical development program of drisapersen for the treatment of Duchenne Muscular Dystrophy (DMD).

Read more »

Clinigen Group Extends Exclusive Agreement with Accord Healthcare to Supply Anti-Cancer Drug Capecitabine into Clinical Trials in Europe

Burton-on-Trent, UK – Clinigen Group plc (AIM: CLIN) today announced that its Clinical Trials Supply business (Clinigen CTS) has extended its exclusive European Union (EU) clinical trial distribution agreement with Accord Healthcare (‘Accord’), a wholly-owned marketing subsidiary of Intas Pharmaceuticals, to include capecitabine, an orally administered chemotherapeutic tablet.

Read more »

Prosensa Regains Rights to Drisapersen from GSK and Retains Rights to All Other Programs for the Treatment of Duchenne Muscular Dystrophy (DMD)

Leiden, The Netherlands and London, UK – Prosensa Holding N.V. (NASDAQ: RNA) and GlaxoSmithKline (GSK) today announced that Prosensa has regained all rights from GSK to drisapersen and will retain rights to all other programs for the treatment of Duchenne Muscular Dystrophy (DMD). This transfer of rights represents the termination of the collaboration agreement between GSK and Prosensa executed in 2009.

Read more »

Dezima Pharma Completes Patient Enrolment for TULIP Phase 2b Study with CETP Inhibitor TA-8995

Naarden, The Netherlands – Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the completed enrolment of its phase 2b TULIP study. The aim of the study is to investigate the effects of TA-8995 (DEZ-001), a potential best-in-class CETP inhibitor, in around 360 patients with mild dyslipidemia on a wide range of plasma lipids, lipoproteins and validated biomarkers of cardiovascular disease (CVD).

Read more »

ARAVIS Strengthens Life Science Team with Three Important Appointments

Zurich, Switzerland – Aravis, the first independent Swiss on-shore private equity house and an established investor in the life science and renewable energy spaces, today announced the appointment of three new members of the life science investment team.

Read more »

Apitope Led Consortium Receives up to €6M FP7 Funding to Develop Novel Therapeutic Vaccine for Graves’ Disease

Bristol, UK and Hasselt, Belgium – Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces that the consortium, led by Apitope, which includes GSK Vaccines, Quintiles and KWS Biotest Limited, has been awarded prestigious Framework Programme 7 (FP7) Health Innovation funding by the European Commission to develop its Graves’ disease therapeutic vaccine, including a Phase I first-in-man study in Graves’ disease patients.

Read more »

Clinigen Group to Provide VIBATIV® to Patients with Hospital-Acquired Bacterial Pneumonia in Europe via Access Program

Burton-on-Trent, UK – Clinigen Group plc (AIM: CLIN) today announced the initiation of an early access program, managed by Clinigen Global Access Programs (Clinigen GAP), to provide the anti-bacterial VIBATIV® (telavancin) to patients in Europe with hospital-acquired bacterial pneumonia (HAP) known or suspected to be caused by MRSA. HAP is an area of considerable unmet need; for the first time VIBATIV® will be available to physicians in Europe to treat eligible patients on an individual named patient basis.

Read more »

DySIS Medical Appoints Robert Cascella as Chairman

Edinburgh, UK –  DySIS Medical Ltd, a medical devices company active within Women’s Health, today announces that Robert Cascella has joined as Chairman of the board of directors of the Company effective January 2014. His appointment further strengthens the board following a year of investment and growth in 2013.

Read more »

e-Therapeutics Provides Update on ETS2101 Phase I Trial in Brain Cancer

Oxford and Newcastle, UK – e-Therapeutics plc (AIM: ETX) today announces that the investigator-led phase I trial of ETS2101 in brain cancer will continue into 2014. Five dose escalation steps have been completed without any drug-related serious adverse events and the investigator therefore intends to enrol further patients at higher dose levels.

Read more »

Nanobiotix 2013 Review: Significant Corporate and Clinical Progress

Paris, France − NANOBIOTIX (Euronext : NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering NanoXray, a novel approach for the local treatment of cancer, summarises its activities and progress made during 2013 and announces its prospective financial communications calendar for the fiscal year 2014.

Read more »

Cell Medica Announces Orphan Drug Designation in the European Union for Cytovir ADV

London, UK  − Cell Medica Limited today announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products has issued a positive opinion on an application for orphan designation of a novel T cell immunotherapy under development by the company.  The cell therapy, Cytovir ADV, targets the treatment of adenovirus infections in patients following allogeneic hematopoietic stem cell (bone marrow) transplant and is comprised of adenovirus-specific T-cells derived from allogeneic donor leukocytes, expanded ex vivo.  Adenovirus infections are a frequent cause of complications and death in patients, particularly children, who have received bone marrow transplants.

Read more »

Imperial Innovations Group plc: Portfolio Company Cell Medica Announces Orphan Drug Designation in the European Union for Cytovir ADV

London, UK − Imperial Innovations Group plc (AIM: IVO, 'Innovations'), a leading technology commercialisationand investment group, welcomes the announcement from portfolio company Cell Medica that its cell therapy Cytovir ADV has been awarded a positive opinion by the European Medicines Agency's Committee for Orphan Medicinal Products.

Read more »

GE to Expand in Life Sciences with Acquisition of Strategic Assets from Thermo Fisher Scientific

Chalfont St. Giles, UK – GE (NYSE:GE) and Thermo Fisher Scientific (NYSE:TMO) announced today that they have entered into an agreement for GE Healthcare to acquire Thermo Fisher’s HyClone™ cell culture media and sera, and gene modulation and magnetic beads businesses for approximately $1.06 billion.  The acquisition will allow GE to expand its offering of technologies for the discovery and manufacturing of innovative new medicines, vaccines and diagnostics in its growing Life Sciences business.

Read more »